17:44 , Nov 16, 2018 |  BC Week In Review  |  Company News

AbbVie strengthens early stage neurology focus with Mission deal

Mission Therapeutics Ltd. (Cambridge, U.K.) and AbbVie Inc. (NYSE:ABBV) partnered to develop deubiquitinase inhibitors for Alzheimer's and Parkinson's diseases. The deal is the second in as many weeks for AbbVie for early stage neurology candidates....
17:33 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Venclexta/Gazyva combo meets PFS endpoint in Phase III for first-line CLL

Genentech Inc. and AbbVie Inc. (NYSE:ABBV) said first-line treatment with Venclexta venetoclax plus Gazyva obinutuzumab met the primary endpoint of improving investigator-assessed progression-free survival (PFS) compared with Gazyva plus chlorambucil in the Phase III CLL14...
16:05 , Nov 16, 2018 |  BC Week In Review  |  Company News

California sues AbbVie over alleged Humira kickbacks

California Insurance Commissioner Dave Jones filed a lawsuit Sept. 18 accusing AbbVie Inc. (NYSE:ABBV) of "systematically and repeatedly" violating the Insurance Frauds Prevention Act by providing kickbacks to healthcare providers throughout California. According to the...
16:01 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures on Nov. 13. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did...
13:00 , Nov 14, 2018 |  BC Extra  |  Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly...
22:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
11:35 , Nov 13, 2018 |  BC Extra  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did existing investors SV...
11:33 , Nov 13, 2018 |  BioCentury  |  Finance

Playing in RNA

M Ventures, the strategic venture arm of Merck KGaA (Xetra:MRK), is adding another RNA company to its portfolio by leading a $30 million series A round for Ribometrix Inc. Fellow new investors Amgen Ventures, Pappas...
20:15 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves Empliciti plus pomalidomide and dexamethasone for MM

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA approved an sBLA for Empliciti elotuzumab in combination with pomalidomide and dexamethasone to treat adults with multiple myeloma patients who have received at least two prior therapies, including lenalidomide...